Immunomedics, GE Healthcare collaborate to evaluate peptide labeling technologies

Immunomedics, Inc. (Nasdaq:IMMU) and GE Healthcare, a business unit of General Electric Company (NYSE:GE), announced today that they have entered into a license and collaboration agreement for the evaluation of labeling technologies based on Immunomedics' patented F-18 peptide labeling method. Terms of the agreement were not disclosed, but GE Healthcare will fund all costs related to this collaboration.

"As reported at the recent annual meeting of the Society of Nuclear Medicine, we have developed a facile and rapid method to label peptides with fluorine-18 (F-18), a radionuclide used in positron-emission imaging," stated Cynthia L. Sullivan, President and CEO of Immunomedics, Inc. "We look forward to GE Healthcare's collaboration with us," added Ms. Sullivan.


Immunomedics, Inc. and GE Healthcare


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Joint ICMRA and WHO statement explains how COVID-19 vaccines are regulated for safety, effectiveness